We didn't try to parse it that finely.
I know that there is a lot of concern out there in the patient community about the impact that these changes will have on drugs for rare diseases.
One of the things that I didn't touch on in my presentation, because I didn't have time, is that one of the changes we made to the guidelines over the course of our consultations was to basically insulate these types of medications from the impact of the lower price ceilings that will result from the application of the new factors. Any product that's going to earn $12 million or less in revenue in Canada won't be impacted in any way, shape or form by the new factors; it will get the median international price—